Department of Neurology, Imam Reza Hospital, Tabriz University of Medical Sciences, Tabriz, Iran; Neurosciences Research Centre, Imam Reza Hospital, Tabriz University of Medical Sciences, Tabriz, Iran.
J Stroke Cerebrovasc Dis. 2013 Nov;22(8):e557-63. doi: 10.1016/j.jstrokecerebrovasdis.2013.06.010. Epub 2013 Jul 18.
Acute ischemic stroke is a major cerebrovascular disease with potential morbidity and mortality. Despite the availability of thrombolytic therapy in some centers, risk factor modification and rehabilitation therapy are the mainstays of stroke management. There is supporting evidence that Ginkgo biloba may afford neuroprotection and improve the outcomes of patients with acute ischemic stroke.
In a double-blind, placebo-controlled, randomized controlled trial, we assessed the efficacy of G biloba on functional outcome in patients with acute stroke. The National Institutes of Heath Stroke Scale (NIHSS) was used to measure functional outcome. A total of 102 patients with acute ischemic stroke were studied. All patients received either G biloba or placebo tablets for 4 months. This trial was registered to the Iranian Registry of Clinical Trials (www.irct.ir; trial IRCT138804212150N1).
There were 52 patients who received G biloba and 50 patients who were in the placebo group. Age, sex distribution, previous medical condition, and laboratory data did not have any significant difference between the 2 groups (P>.05). The mean difference of 4-month follow-up NIHSS scores and NIHSS scores at admission was 4.7±2.7 and 4.1±3.0 in the G biloba and placebo groups, respectively (P>.05). The primary outcome-a 50% reduction in the 4-month follow-up NIHSS score compared to the baseline NIHSS score-was reached in 17 patients (58.6%) and 5 patients (18.5%) in the G biloba and placebo groups, respectively (P<.05). The risk ratio and number needed to treat were 3.16 (confidence interval 1.35-7.39) and 2.50 (confidence interval 1.58-5.90), respectively. In addition, multivariate regression adjusted for age and sex revealed a significant NIHSS decline in the G biloba group compared to the placebo group (P<.05).
Our data suggest that G biloba may have protective effects in ischemic stroke. Therefore, the administration of G biloba is recommended after acute ischemic stroke.
急性缺血性脑卒中是一种具有潜在发病率和死亡率的主要脑血管疾病。尽管一些中心可提供溶栓治疗，但危险因素的改变和康复治疗仍是脑卒中管理的主要方法。有证据表明，银杏叶可能提供神经保护作用，并改善急性缺血性脑卒中患者的结局。
在一项双盲、安慰剂对照、随机对照临床试验中，我们评估了银杏叶对急性脑卒中患者功能结局的疗效。使用国立卫生研究院卒中量表（NIHSS）来衡量功能结局。共研究了 102 例急性缺血性脑卒中患者。所有患者均接受银杏叶或安慰剂片剂治疗 4 个月。该试验在伊朗临床试验注册中心（www.irct.ir；试验注册号：IRCT138804212150N1）注册。
52 例患者接受银杏叶治疗，50 例患者接受安慰剂治疗。两组患者的年龄、性别分布、既往病史和实验室数据无显著差异（P＞.05）。银杏叶组和安慰剂组在 4 个月随访 NIHSS 评分和入院时 NIHSS 评分的平均差值分别为 4.7±2.7 和 4.1±3.0（P＞.05）。主要结局为与基线 NIHSS 评分相比，4 个月随访 NIHSS 评分降低 50%，银杏叶组和安慰剂组分别有 17 例（58.6%）和 5 例（18.5%）患者达到（P＜.05）。风险比和需要治疗的例数分别为 3.16（置信区间 1.35-7.39）和 2.50（置信区间 1.58-5.90）。此外，经年龄和性别调整的多变量回归显示，银杏叶组 NIHSS 评分较安慰剂组显著下降（P＜.05）。
我们的数据表明，银杏叶可能对缺血性脑卒中具有保护作用。因此，建议在急性缺血性脑卒中后使用银杏叶。
Zotero 插件